Changing the Face of Modern Medicine: Stem Cells & Gene Therapy, October 18–21, 2016, Florence, Italy  by Stuckey, Daniel W.
EBioMedicine 14 (2016) 3–4
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comIn FocusChanging the Face of Modern Medicine: Stem Cells & Gene Therapy,
October 18–21, 2016, Florence, ItalyDaniel W. Stuckeyhttp://dx.doi.org/10.1016/j.ebiom.2016.11.028
2352-3964/© 2016 The Author. Published by Elsevier B.Va r t i c l e i n f oArticle history:
Received 22 November 2016
Accepted 22 November 2016
Available online 25 November 2016
Myocardial infarction (MI) occurs when blood ﬂow to the heart is
prevented, usually as a result of a blood clot. This can cause damage to
the heart muscle, resulting in death of cardiac tissue which is replaced
with collagen scar tissue. Scar tissue is not contractile and does not pos-1. Treating Age-related Macular Degeneration Using Human
iPS Cells
Age-related macular degeneration (AMD) is a medical condi-
tion of the eye that results in blurred vision and/or a loss of central
vision. The wet form of AMD – caused by abnormal blood vessel
growth – is often treated using anti-VEGF medication. This ap-
proach can slow deterioration but is unable to treat the cause, or
reverse the effects of, retinal pigment epithelium (RPE) atrophy.
A regenerative medicine strategy currently being explored is the
possibility that healthy RPE tissue could replace defective RPE.
Masayo Takahashi from the RIKEN Center for Developmental Biol-
ogy (Kobe, Japan) presented data on the creation and utilization
of RPE cells from inducible pluripotent stem cells (iPSCs) to treat
wet AMD. In 2014, Takahashi led a pilot study of the ﬁrst transplant
of human iPSC-derived tissue into a human being. Skin cells taken
from a patient suffering from wet-AMD were converted into
iPSCs, differentiated into RPE cells and transplanted back into the
patient's eye. Importantly, transplanted cells were not rejected
and resulted in the stabilization of visual acuity. However, using
autologous cells is a costly option and is of limited use to patients
with acute ocular diseases. To address these points, Takahashi has
explored the therapeutic use of RPE cells from iPSCs derived from
human leukocyte antigen (HLA)-matched homozygote donors.
When tested in a monkey model, no rejection signs were observed
in monkey iPSC-RPE allografts of MHC-matched animal models,
whereas immune attacks around the graft were detected in the
MHC-mismatched situation. Using an in vitro assay to assess the
immune response in a quasi-human context, T cells were unable
to respond to human iPSC-RPE cells derived from HLA homozygous
donors. This encouraging result indicates that the allogeneic option
is viable and should be tested in future clinical trials if the donor
and recipient are HLA matched.. This is an open access article under2. Remuscularization of Injured Hearts with Human ESC-Derived
Cardiomyocytes
sess the electrical conductivity of cardiac tissue, putting the patient at
risk of heart failure and arrhythmias. Michael Laﬂamme (University
Health Network, Toronto, Canada) presented preclinical data on the
use of human embryonic stem cell-derived cardiomyocytes (hESC-
CMs) to improve the function of infarcted hearts. Using a guinea pig
model, when hESC-CM cells were grafted into injured hearts they
were able to integrate into host heart muscle. Shared gap junctions be-
tween these tissues were observed alongwith an improvedmechanical
function in treated animals. To test host-graft electrical coupling, grafted
tissuewas labelledwith a genetically-encoded calcium sensor. Host ECG
could be correlated to calcium ﬂux in donor tissue, demonstrating a cer-
tain degree of 1:1 host-graft coupling in damaged hearts. To determine
if this approach could be translated into larger animal models where
many more cells would be needed, a non-human primate model of
myocardial ischemia-reperfusion was utilized. Macaques with MI
were treated with 1 billion hESC-CMs, delivered to and around the in-
farct region. Autopsy showed signiﬁcant remuscularization of the in-
farcted heart, with reciprocal gap junctions and integration of host
vasculature into donor tissue. However, in contrast to small animal
models, small non-fatal arrhythmias were observed in engrafted ma-
caques. These results suggest that hESC-CM grafts are able to improve
the function of infarcted hearts, but the challenge is to improve electri-
cal properties of the graft to minimize arrhythmic complications. The
next step is to reﬁne this promising approach in a pig MI model which
is more faithful to the human situation.
3. First Application of Gene-edited ‘Universal’ T Cells for Leukemia
Chemotherapy has been used with great success to treat patients
with leukemia. Unfortunately, this approach is not always effective, es-
pecially when cancerous cells become refractory through resistance
mechanisms. Until recently, palliative care has been the only option
left for patients suffering from aggressive drug-resistant leukemia.
However, developments in the ﬁeld of immunology are revolutionizing
the way hematological cancers are tackled. Waseem Qasim (University
College, London) presented one such strategy that is being used withthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Leukemia (B-ALL). Essentially, T cells derived from healthy donors
were molecularly tweaked using genome editing technology. These
so-called UCART19 cells express chimeric antigen receptors (CARs)
that target surface CD19 proteins found on leukemic cells, and kill
them. CART19 cells were initially tested in two extremely sick children
with relapsed B-ALL. Using a special license allowing application of un-
licensed medical products, CART19 cells were administered. This was a
landmark experiment in which gene-edited therapeutic T cells were
being tested in humans for the ﬁrst time. Both patients responded re-
markably well to the treatment, showing robust abolition of leukemic
cells. This pioneering study informed the dosing and schedule of a
Phase 1 trial to evaluate the safety and ability to induce molecular re-
mission in pediatric patients with relapsed/refractory CD19-positive
B-ALL, taking place at Great Ormond Street hospital (NCT02808442).
This trial is currently recruiting participants and hopes to prove the ef-
fectiveness of UCART19 cells in larger groups of patients. Similar studies
are needed to test if this therapeutic approach can be expanded to treat
other aggressive forms of chemotherapy-resistant cancer.
4. Generating a Kidney From Human Pluripotent Stem Cells: Where
to From here?
In a plenary session dedicated to new technologies, Melissa H. Little
from the University of Melbourne (Melbourne, Australia), discussed the
generation of kidney organoids from hPSCs and posed the question:
where to from here? Approximately 10% of Australian's suffer from
chronic kidney disease, driving the need to better model diseases in
the laboratory to dissect etiological mechanisms, screen therapeutic
agents and explore the possibility of regenerative applications. Little
presented a protocol to differentiate hPSCs into all four kidney progen-
itor populations (nephron, ureteric epithelial, renal interstitial and en-
dothelial), that could be further directed to form self-organized kidney
organoids. Detailed analysis of these 3D organoids identiﬁed at least
nine different kidney cell types, and transcriptional proﬁling indicated
similarity to that of aﬁrst trimester fetal kidney. Functional testing dem-
onstrated that these kidney organoids exhibit some of the actions of an
intact kidney, including formation of a brush border within the proxi-
mal tubules that can absorb nutrients. These structures also express
multiple drug transporters that respond to nephrotoxins, making
them appropriate for drug screening assays. However, fundamental
processes such as blood ﬁltration and urine production are not present
and introducing additional steps or bioengineering methods to reﬁne
the protocol might expand organoid functionality. Nevertheless, creat-
ing kidney organoids from patient-derived iPSCs provides a means to
understand and validate novel mutations. One third of kidney diseases
are inherited, so recapitulating renal kidney disease in the dish will en-
able the development of mutation-speciﬁc therapies and even correct
the mutation using gene editing technologies. Perhaps in the future,
corrected kidney organoids could be transplanted back into the patient
to replace defective kidney tissue. Organoids recapitulatingmanydiffer-
ent body parts have now been created, providing an in vitro platform to
model disease and test therapeutic interventions.
5. Genome Engineering Using CRISPR-Cas: Prospects and Challenges
Feng Zhang from The Broad Institute MIT (Cambridge, USA) gave an
inspiring talk on the prospects and challenges of genome engineering.
The presentation covered two main topics. First, strategies to improve
the speciﬁcity of genome editing were discussed. A propensity forRNA-guided nucleases to cut at non-speciﬁc sites, resulting in unintend-
ed mutagenesis, has hampered the use of CRISPR-Cas in situations re-
quiring high levels of speciﬁcity. Zhang's approach to tackle this issue
was to use structure–guided protein engineering of Streptococcus
pyogenes Cas9 (SpCas9), to abolish off-target effects while preserving
on-target activity. The crystal structure of SpCas9:DNA indicated that
positively charged amino acids were found in the cleft of SpCas9 that
holds the negatively charged non-target DNA strand. These residues
could be systematically substituted for neutral amino acids to reduce
this binding and, in theory, necessitate more stringent base pairing be-
tween the RNA guide and target DNA strand to improved speciﬁcity. In-
deed, a number of mutants were identiﬁed that were able to reduce off-
target activity by at least 10-fold compared to wildtype SpCas9, while
maintaining on-target cleavage activity. The second topic discussed
was how bacterial diversity could be explored to identify new CRISPR-
Cas systems. To date, only two Class 2 nucleases – thosewith a single ef-
fector subunit – have been described, Cas9 and Cpf1. This runs counter
to the extreme diversity shown by microbes that are likely to have
evolved additional Class 2 variants. Using a computational prediction
approach across microbial genome sequences, new candidate Class 2
CRISPR-Cas9 loci were identiﬁed. A total of 53 loci were discovered,
that were divided into three distinct groups based on the nature of
their effector proteins, denoted C2c1–3 (Class 2 candidate 1–3). The
functionality of these Class 2 variants are currently being tested, and
will perhaps offer novel mechanisms of action to expand the CRISPR-
Cas toolkit.
6. Use of Adipose Stem Cells to Treat Inﬂammatory Diseases
In a session dedicated to MSC Gene & Cell Therapy, Wilfried
Daelemans from TiGenix (Leuven, Belgium), presented data on the use
of expanded allogeneic Adipose-derived Mesenchymal Stem Cells
(ASCs) to treat inﬂammatory disorders. The rationale for using ASCs is
that they possess anti-inﬂammatory and immunomodulatory potential,
whilst being well tolerated. ASCs are separated from liposuction-de-
rived adipose fat, characterized, expanded and stored in a cell bank
until required. The use of ASCs in a variety of preclinical mouse models
of inﬂammation were presented. Administration of ASCs resulted in de-
creasing the severity of established arthritis in a collagen-induced
mouse model for rheumatoid arthritis, primarily by restoring the Treg
compartment in treated animals. Similarly encouraging results were
seen in a dextran sulfate sodium-induced model of colitis, and in both
lipopolysaccharide and cecal ligation and puncture models of sepsis
ASC-treated mice showed decreased mortality compared to non-treat-
ed controls. To illustrate the success of this approach in humans, results
from a recently completed clinical trial were highlighted. This Phase 3
randomized, multicenter trial aimed to evaluate the safety and efﬁcacy
of allogeneic ASCs (Cx601) for treatment of treatment-refractory com-
plex perianal ﬁstulas in Crohn's disease patients (NCT01541579). The
primary endpointwasmetwith half of the patients treatedwith a single
injection of Cx601 achieving remission at week 24. Cx601 was well tol-
erated in the studypopulation and no immune reaction or speciﬁc treat-
ment emergent adverse events were detected. Follow-up analysis at
52 weeks conﬁrmed the sustained efﬁcacy and safety proﬁle of Cx601.
As a result of these encouraging results, TiGenix has submitted a
Marketing Authorization Application to the EMA and is preparing to de-
velop Cx601 in the United States after having reached an agreement
with the FDA. Other ASC products are in the clinical pipeline at TiGenix
to treat a range of inﬂammatory diseases that are treatment-refractory,
underscoring the clinical utility of ASCs as a therapeutic entity.
